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esponsibility of Xi’Abstract The aim of this study was to develop and validate a simple, sensitive, precise and cost-effective one-
level agar diffusion (5þ1) bioassay for estimation of potency and bioactivity of Levoﬂoxacin in pharmaceutical
preparation which has not yet been reported in any pharmacopoeia. Among 16 microbial strains, Bacillus pumilus
ATCC-14884 was selected as the most signiﬁcant strain against Levoﬂoxacin. Bioassay was optimized by
investigating several factors such as buffer pH, inoculums concentration and reference standard concentration.
Identiﬁcation of Levoﬂoxacin in commercial sample Levoﬂox tablet was done by FTIR spectroscopy. Mean
potency recovery value for Levoﬂoxacin in Levoﬂox tablet was estimated as 100.90%. A validated bioassay
method showed linearity (r2¼0.988), precision (Interday RSD¼1.05%, between analyst RSD¼1.02%) and
accuracy (101.23%, RSD¼0.72%). Bioassay was correlated with HPLC using same sample and estimated
potencies were 100.90% and 99.37%, respectively. Results show that bioassay is a suitable method for estimation
of potency and bioactivity of Levoﬂoxacin pharmaceutical preparations.
& 2014 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Levoﬂoxacin is a synthetic broad-spectrum antibiotic of ﬂuoroqui-
nolone group and is used to treat severe bacterial infections whichsity. Production and hosting by Else
7
s: CSIR-National Environmental
Nagpur, India.
mail.com,
an Jiaotong University.failed to respond to other antibiotic classes [1,2]. Levoﬂoxacin is
chemically(S)-9-ﬂuoro-2, 3-dihydro-3-methyl-10-(4-methylpiperazin-
1-yl)-7-oxo-7 H-pyrido [1,2,3–de]-1, 4 benzoxazine-6-carboxylic
acid hemihydrate (Fig. 1) with molecular formula C18H20FN3O4,
1
2H2O and a molecular weight of 370.4 [3]. It is a yellowish white to
yellow powder [3,4].
Levoﬂoxacin is active against both Gram-positive and Gram-
negative bacteria [5]. It is used in the treatment of bronchitis,
urinary tract infections, pneumonia, skin and soft tissues infections
[6]. This antibiotic can also be used to prevent infection after
exposure to inhaled anthrax. Levoﬂoxacin inhibits bacterialvier B.V. All rights reserved.
.H2O
Fig. 1 Chemical structure of Levoﬂoxacin.
Validated microbial bioassay for quantiﬁcation of Levoﬂoxacin 19topoisomerases II, topoisomerases IV and DNA gyrase, which are
important enzymes required for DNA replication, transcription,
repair and recombination, thereby inhibiting cell division [6,7].
Among all pharmaceutical products, the most commonly faked
and adulterated ones are antibiotics probably because the fre-
quency of their use is very high [8]. The misuse of antibiotics
fosters the increase and spread of antibiotic resistance and may
lead to superinfections [9]. An important factor in the development
of drug-resistant strains of microorganisms is that many antibiotics
are bacteriostatic rather than bactericidal [10]. In order to over-
come the resistance problem and for the safe use of antibiotics, the
correct measurement of potency and bioactivity of antibiotics is
essential. Due to the increased resistance problem, the quantiﬁca-
tion of the actual concentration of active ingredients in antibiotic
preparation is critical. A mild difference in the concentration of
active ingredient in antibiotic preparations may have impact on
actual efﬁcacy. Therefore, quantiﬁcation of active pharmaceutical
ingredient (API) in antibiotic preparation is very necessary because
most of the time these drugs are the lines that separate life from
death [11]. These substances in very low concentrations are known
to totally destroy or partially inhibit microorganisms [12].
The potency of antibiotics can be determined by chemical
and biological methods. Chemical methods such as capillary
electrophoresis, ultraviolet (UV) spectrophotometry, high per-
formance liquid chromatography (HPLC) and high performance
thin layer chromatography (HPTLC) have been used for the
quantitative determination of Levoﬂoxacin in formulations as
well as in human urine, and serum [6,13]. However, the
microbiological assay for determination of potency of Levo-
ﬂoxacin has not yet been reported in any pharmacopoeia.
Biological method is the most convenient way to determine
the potency of antibiotics [14].
Determination of antimicrobial potency is extremely important
for the quality control and quality assurance concerning pharma-
ceutical preparations, being thus necessary to develop practical and
economical methods which can be applied in the validation and
dosage of drugs [15,16]. The application of microbiological assay
has been recently developed for intravenously administered anti-
biotics. This method is highly acceptable by regulating authorities
to control antibiotic potency [17,18]. Microbiological bioassay
plays an essential role in the manufacturing and quality control of
antibiotic medicines and demands considerable skill and expertise
to assure success [18,19]. Microbiological assay helps in estimat-
ing active constituents, biological activity and in monitoring the
stability of antibiotics. Any small change in the antibiotic
molecule, which may not be detected by chemical methods, will
be revealed by a change in antimicrobial activity [4]. Hence,
microbiological assay is very useful for resolving doubts regarding
possible change in potency of antibiotics and their preparations.
A microbial bioassay requires effective and fully characterized
microbial strains. The identiﬁcation and characterization of micro-
bial strain are performed by culturable and non-culturable techni-
ques [20,21].The potency of antibiotics can be measured by microbial
bioassay, in which their inhibitory effect on the growth of test
microorganisms is evaluated [3,4,14,22]. Bioassays do not require
specialized equipment or toxic solvents [23]. The agar diffusion
method widely used in antibiotic assay relates the size of the zone
of inhibition to the dose of the antibiotic assayed. The relation of
the diameter of inhibitory zones to concentration of antibiotic in a
solution applied in cups has been considered theoretically [24,25].
The ability of an antibiotic is to inhibit or to kill the growth of
living microorganisms. The inhibition of microbial growth in
standardized conditions may be utilized for demonstrating the
therapeutic efﬁcacy of antibiotics. The antimicrobial activity of
Levoﬂoxacin in ophthalmic solution was measured using Bacillus
subtilis, ATCC-6633 [26]. The in vitro activity of Levoﬂoxacin
was evaluated against 234 strains of Mycobacterium tuberculosis
and MIC50 and MIC90 were obtained as 0.25 mg/L and 0.5 mg/L,
respectively [27].
The proposed article focuses on the development and validation
of a simple, sensitive, accurate, precise and cost-effective one-level
agar diffusion (5þ1) bioassay for the quantiﬁcation of potency and
bioactivity of Levoﬂoxacin in pharmaceutical preparations.2. Materials and methods
2.1. Chemicals and reagents
Chemicals and reagents used were of analytical grade (Merck Ltd.,
Mumbai). Milli-Q water (Millipore) was used to prepare solutions.
United States Pharmacopoeia (USP) reference standard of Levo-
ﬂoxacin was used for standard solution preparation. Commercial
sample Levoﬂox tablet containing Levoﬂoxacin 500 mg was
obtained from the local market.
2.2. Equipment
All equipments used for the bioassay study were calibrated and
validated. Sterilized glassware (Class B) such as Petri plates, test
tubes, volumetric ﬂasks, pipettes and sterile borer were used in the
experiment. Steam Sterilizer/Autoclave (Make-Nat steel) was used
to sterilize the media at 121 1C and 15 psi for 15 min. Glycerol
stocks of microbial cultures stored at –80 1C Deep freezers (Make
– Haier) were used as test strains. Identiﬁcation of Levoﬂoxacin
was performed by an FTIR spectroscope (Perkin Elmer) and
HPLC (Make-Agilent Technologies) was used for comparative
study. Bioassay plates were incubated at 37 1C inside the incubator
(Make-Thermolab) for bacterial growth. Zones of inhibition were
measured by an antibiotic zone reader (Make-Aarachal
Corporation).
2.3. Test microbial strains
Microbial cultures were procured from American Type Culture
Collection (ATCC), USA, and National Collection of Type
Cultures (NCTC), UK. The different Gram-positive bacteria
Bacillus cereus (ATCC-11778), B. pumilus (ATCC-14884),
B. subtilis (ATCC-6633), Staphylococcus aureus (ATCC-6538,
29737, 9144), Staphylococcus epidermidis (ATCC-12228),
Kocuria rhizophila (ATCC- 9341), Micrococcus luteus (ATCC-
10240) and Gram-negative bacteria Escherichia coli (ATCC-
10536, 8739), Salmonella abony (NCTC-6017), Pseudomonas
N.A. Dafale et al.20aeruginosa (ATCC-25619, 9027), Klebsiella pneumoniae (ATCC-
10031), Bordetella bronchiseptica (ATCC-4617) were used in
microbiological bioassay.
2.4. Preparation of phosphate buffer
pH has a major inﬂuence on the response of antibiotics upon
indicator microorganisms. The experiments were performed with
different pH buffers. Buffer solutions of different pH were
prepared by dissolving various quantities of K2HPO4 and KH2PO4
in sufﬁcient Milli-Q water. The pH was adjusted with 8 M
phosphoric acid or 10 M potassium hydroxide and sterilized in
autoclave [3].
2.5. Preparation of microbiological media
Dehydrated media were procured from Hi-Media Ltd., Mumbai
(India). Primary objective of the media was to support the rapid
growth of indicator microorganism being used in the bioassay.
Antibiotic assay medium No.11 was used as a bioassay medium to
prepare the base layer and the seed layer. Soyabean casein digest
agar media were used for slant preparation for bacterial growth.
Dehydrated media were dissolved in the distilled water and pH
was adjusted as per instructions on the dehydrated media
container. Media were sterilized in the autoclave at 121 1C and
15 psi for 15 min.
2.6. Preparation of standard solution
Accurately weighed quantity of reference standard of Levoﬂoxacin
25.0 mg was dissolved in phosphate buffer and till the volume was
25 mL to obtain 1000 mg/mL of Levoﬂoxacin. Five standard
dilutions, i.e., S1 (2.56 mg/mL), S2 (3.20 mg/mL), S3 (4.00 mg/mL),
S4 (5.00 mg/mL), and S5 (6.25 mg/mL), were prepared in stepwise
increasing concentration of 4:5. Dilution S3 was considered
as the reference concentration (mean concentration) level of
standard.
2.7. Preparation of sample solution
Twenty tablets were weighed and pulverized. A quantity of
powder equivalent to 25.0 mg of the commercial sample Levoﬂox
tablet was accurately weighed and transferred into a 25 mL
volumetric ﬂask. The ﬁnal volume was made up to 25 mL
with phosphate buffer to obtain a concentration of 1000 mg/mL.
From this stock, a solution with a concentration of 100 mg/mL was
prepared and ﬁnally a dilution i.e., “T”, was made which was
equivalent to the mean reference standard concentration (S3).
2.8. Inoculums preparation and its standardization
Effective and fully characterized microbial strain is required for
the bioassay. Fresh microbial strains preserved on glycerol stock
were revived and then sub-cultured on the slants of soybean casein
digest agar media. Slants were incubated at 37 1C for 24 h for
bacterial growth. Fresh culture slants were used throughout the
study. About 3 mL sterilized saline solution (0.9%) was used to
wash the microorganism from agar slant and then the dilution
factor was determined, which gave 25% light transmission at about
530 nm.2.9. Bioassay method
The 5þ1 bioassay design with standard curve was carried out
by the cylinder-plate method. This method depends upon
diffusion of the antibiotic solution from a vertical cylinder or
cavity through a solidiﬁed agar layer in a Petri plate to an extent
such that growth of the added microorganism is prevented
entirely in a zone around the cylinder or cavity containing a
solution of the antibiotic [3]. Standardized microbial suspension
was used to prepare double-layer plates of Assay medium No.11
by pouring 4 mL seed layer (inoculated with the desired strain)
over a solidiﬁed 21 mL base layer of assay medium in a
100 mm 20 mm Petri dish [4]. These plates were left for
30 min for solidiﬁcation. After media solidiﬁcation, 5 mm-
diameter wells were bored at six points for a 5þ1 bioassay
design (Fig. 2). 100 mL of each standard or test solution was
pipetted into individual wells. Five Petri dishes were used for
each assay in order to test the reference concentration (S3)
concomitantly with each standard or sample concentration. The
plates were left standing for 1–4 h at room temperature as a
period of pre-incubation diffusion to minimize the effects of
variation in time between the applications of the different
solutions. The plates were incubated at 37 1C for 24 h.
After the complete incubation period, the diameters (in mm)
of the inhibition zones were accurately measured by a zone
reader and the results were observed. Assay plates were tested
in triplicate, resulting in nine measures of each of the
standards S1, S2, S4 and S5 and the test sample “T”. The
reference concentration “S3” was tested 36 times with the
lowest and the highest concentration of standards and 9 times
with the test sample in order to ﬁt the data obtained in all the
dishes. The average of all readings of solution “S3” and the
readings of the concentration tested on each of the sets of three
plates and the average of all the 36 readings of “S3” were
estimated. The average of the 36 reading of solution “S3” was
the correction point for curve. Highest and lowest zone
diameters for ﬁnal potency calculation were obtained by the
following equations:
L¼ 3aþ 2bþ c–e
5
; H ¼ 3eþ 2d þ c–a
5
where L is the zone diameter for the lowest concentration of the
standard curve response line; H is the zone diameter for the
highest concentration of the standard curve response line; c is
the average zone diameter of 36 readings of the reference point
standard solution; and a, b, d, and e are the corrected average
values for the other standard solutions, lowest to highest
concentrations.2.10. FTIR spectroscopy analysis
Fourier transform infrared (FTIR) spectroscopy analysis was used
to ascertain the presence or absence of Levoﬂoxacin in the market
tablet sample (Levoﬂox). Identiﬁcation of Levoﬂoxacin was
performed by FTIR spectroscopy using Perkin Elmer system
(Modal-Spectrum one). The commercial sample (Levoﬂox) and
reference standard were prepared in the form of discs dispersed in
potassium bromide (IR grade) and the spectra were recorded
between 2000 cm1 and 400 cm1 under the same operational
conditions.
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Fig. 2 One-level agar diffusion bioassay (5þ1 assay): Five Petri dishes represent the reference solutions S1 (2.56 mg/mL), S2 (3.20 mg/mL), S3
(4.0 mg/mL), S4 (5.0 mg/mL) and S5 (6.25 mg/mL). “T” represents the sample solution (4.0 mg/mL).
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The speciﬁcity of the proposed bioassay was compared with HPLC.
The HPLC assay was carried out on a system of Agilent Technol-
ogies, Series 1200, which is composed of a quaternary pump, an
autosampler, a photodiode array detector (DAD) and EZ Chrome
Elite software. The column used was a Cosmosil C18 MS II from
Thermo Electron Corporation. The mobile phase consisted of a
mixture of 85 volume of buffer solution prepared by dissolving 84
volumes of 0.05 M citric acid monohydrate and 1 volume of 1 M
ammonium acetate; and 15 volumes of acetonitrile. A 0.1% (m/v)
solution of Levoﬂoxacin reference standard was prepared in 0.1 M
hydrochloric acid and 5 mL of this solution was diluted to 50 mL
with distilled water. The test solution was prepared by dissolving a
quantity containing 100 mg of the commercial sample Levoﬂox tablet
and dispersed in 100.0 mL of 0.1 M hydrochloric acid. 5 mL of this
solution was diluted to 50 mL with distilled water. All solutions were
ﬁltered through 0.45 mm membrane ﬁlter before injection. The
spectrophotometer was set at 293 nm. Flow rate was maintained as
1 mL/min and the injection volume was 10 mL.3. Results
3.1. Selection of signiﬁcant microbial strain
The criteria for selection of signiﬁcant microbial strain were well-
deﬁned edges and large measurable zone diameter under antibiotic
treatment. The 16 bacterial strains were tested for their response
and susceptibility against Levoﬂoxacin. Among all tested strains,
B. pumilus ATCC-14884 showed the most signiﬁcant result at the
same conditions. Hence, B. pumilus ATCC-14884 strain was used
further for one-level (5þ1) bioassay study.3.2. Effect of pH on zone diameter
The growth rate of microorganisms is highly inﬂuenced by buffer
pH. The activity of Levoﬂoxacin was studied in the range of
phosphate buffer pH 6.0–8.0. The phosphate buffer pH 7.0 was
selected as the most suitable for signiﬁcant growth of B. pumilus
ATCC-14884 and production of measurable sharp zone of inhibi-
tion. The effect of different buffer pH solutions on zone of
inhibition is shown in Table 1.
3.3. Selection of optimum inoculums concentration
Wide variation in the number of microorganism produced different
diameters of zone of inhibition. An experiment was performed to
determine how critical the concentration of inoculums might be in the
present system when other factors were constant. Optimum inoculum
concentration was selected based on zone diameter with edge sharpness.
Small zone diameter and overlapping of growth pattern were observed
with high inoculum concentration, whereas larger zone diameter and
very poor growth were observed with too diluted inoculums concentra-
tion. Optimum inoculum concentration should lie in between these two
extremes. In the present study, six different inoculums concentrations,
i.e., 0.5%, 1.0%, 1.5%, 2.0%, 2.5% and 3.0%, were tested and their
effects on diameter of zone of inhibition were observed (Table 2). All
the inoculums concentrations were optimized at 25% transmittance and
optimum inoculum concentration of B. pumilus ATCC-14884 for
microbial bioassay was selected as 2.0%.
3.4. Determination of optimum antibiotic concentration
The optimization of antibiotic concentration is very important to
overcome the resistance problem and for safe use of antibiotics.
Table 2 Effect of different inoculum concentrations on the
diameter of zone of inhibition.
Inoculum
concentration
(%)
Dilution
factor
(mg/mL)
Zone
diameter
(mm)
Observation
0.5 4 34.8 Very light and large zone
1.0 4 29.0 Light and large zone
1.5 4 26.9 Light and large zone
2.0 4 22.6 Very sharp and clear zone
2.5 4 19.8
Overlapped zone with
hazy growth
3.0 4 16.8
Overlapped zone with
hazy growth
Table 1 Response of microbial strains to Levoﬂoxacin (4.0 mg/mL) at different buffer pH.
Name of organisms Zone diameter (mm) Results
pH 6.0 pH 6.5 pH 7.0 pH 7.5 pH 8.0
Bacillus cereus (ATCC-11778) 19.2 19.7 20.5 20.3 19.9 Sharp zone
Bacillus pumilus (ATCC-14884) 21.1 21.8 22.5 21.7 20.4 Very sharp & clear zone
Bacillus subtilis (ATCC-6663) 23.9 24.1 24.7 24.5 24.1 Large zone
Staphylococcus aureus (ATCC-6538) 19.5 19.7 20.1 20.4 19.9 Sharp zone
Staphylococcus aureus (ATCC-29737) 25.4 25.7 26.5 26.0 25.9 Large zone
Staphylococcus aureus (ATCC-9144) 19.6 19.8 20.4 20.2 19.7 Sharp zone
Staphylococcus epidermidis (ATCC-12228) 18.8 19.0 19.6 19.9 20.0 Intermediate zone
Kocuria rhizophila (ATCC-9341) 17.5 18.0 19.4 19.1 19.2 Intermediate zone
Micrococcus luteus (ATCC-10240) 17.9 18.2 18.5 18.7 19.4 Intermediate zone
Escherichia coli (ATCC-10536) 19.4 19.9 20.5 21.5 22.7 Sharp zone
Escherichia coli (ATCC-8739) 19.0 19.8 20.6 20.9 21.6 Sharp zone
Salmonellae abony (NCTC-6017) 25.7 26.2 26.8 27.0 27.1 Large zone
Pseudomonas aeruginosa (ATCC-25619)      No inhibition zone
Pseudomonas aeruginosa (ATCC-9027)      No inhibition zone
Klebsiella pneumoniae (ATCC-10031)      No inhibition zone
Bordetella bronchiseptica (ATCC-4617) 24.9 25.4 25.7 25.8 25.6 Large zone
Table 3 Effect of different concentrations of reference
standard of Levoﬂoxacin on zone of inhibition.
Standard concentration (mg/mL) Mean zone diameter (mm)
2.56 19.6
3.20 21.8
4.00 22.9
5.00 24.5
6.25 26.7
N.A. Dafale et al.22The 5þ1 bioassay design (One-level assay) was used to quantify the
potency of Levoﬂoxacin. One-level assay design involved the
preparation of ﬁve sets of concentration for standard in stepwise
increasing ratio of 4:5. The effect of all these standard concentrations
on the zone of inhibition is depicted in Table 3. All concentrations
were used in triplicate and assigned as S1, S2, S3, S4 and S5, which
represent lower to higher concentration with increasing ratio 4:5.
“S3” represents the reference concentration (mean concentration) of
Levoﬂoxacin reference standard and was used as a correction factor.
The optimum antibiotic concentration “S3” was estimated as 4 mg/mL.3.5. Percentage potency calculation
The correction in zone diameter with standard was carried out by
taking average zone diameter of the standard mean concentration
“S3” separately for each of the standard response line concentrations
S1, S2, S4, and S5. Similarly average zone diameter of standard
response line concentrations (S1, S2, S4, and S5) was taken. All the 36
responses of “S3” were averaged for all the four sets of plates. The
average of the 36 responses of “S3” was considered as the correction
point of the response line and by putting these values in the standard
equation the percentage potency was calculated as 100.90%.
3.6. Method validation
All the parameters of the bioassay were optimized prior to
validation to accurately estimate the performance of the proposed
bioassay method. The bioassay method was validated by evaluation
of linearity, precision, accuracy and robustness according to the
International Conference on Harmonization [28].
3.6.1. Linearity
To evaluate the linearity of assay, ﬁve concentrations of standards,
i.e., 2.56, 3.20, 4.0, 5.0 and 6.25 mg/mL, were used. A calibration
curve for log10 of concentrations (mg/mL) of Levoﬂoxacin versus
zone of inhibition (mm) was plotted and the obtained data were
subjected to regression analysis by the least squares method. The
representative linear equation was y¼1.69xþ18.03. The determi-
nation coefﬁcient (r2¼0.9883) obtained was highly signiﬁcant for
the method.
3.6.2. Precision
Precision was determined by repeatability and intermediate preci-
sion and was expressed as the relative standard deviation (RSD).
The repeatability was examined by assaying the six replicates of
commercial samples (Levoﬂox) at 100% concentration level, i.e.,
4 mg/mL against the reference standard of Levoﬂoxacin on the
same day (intraday) by the same analyst under the same experi-
mental condition (Table 4). The intermediate precision of bioassay
Table 4 Repeatability of the bioassay with a commercial
sample of Levoﬂox tablet.
Theoretical
amount
(mg)
Experimental
amount
(mg)
Potency
(%)
Mean
potency
(%)
RSD
(%)
500 507.6 101.52 100.90 1.09
503.0 100.60
514.2 102.84
499.4 99.88
502.1 100.42
500.7 100.14
Table 5 Intermediate precision data of bioassay of Levo-
ﬂoxacin in a commercial sample Levoﬂox tablet.
Precision Observed
potency (%)
Mean
potency (%)
RSD (%)
Inter-day precision
Day 1 100.84 100.48 1.05
101.82
Day 2 99.62
99.66
Inter-analyst precision
Analyst 1 100.06 100.66 1.02
99.56
Analyst 2 101.84
101.18
Table 6 Accuracy of microbial bioassay determined for
Levoﬂoxacin.
Theoretical
potency
(%)
Observed
potency
(%)
Mean
potency
(%)
Accuracy
(%)
RSD
(%)
80 81.78 81.62 101.23 0.72
80.92
82.17
100 100.58 100.59
99.96
101.25
120 121.08 121.29
120.84
121.96
Table 7 Factors investigated in the robustness test.
Factors Parameters Potency
(%)
RSD
(%)
Solvent Distilled water 100.12 0.47
100.38
99.47
Inoculum 1.5% 99.92 0.41
concentration 99.49
100.31
Incubation 30 1C 99.96 0.55
temperature 100.29
101.04
Validated microbial bioassay for quantiﬁcation of Levoﬂoxacin 23was estimated by performing the analysis in the same laboratory
on 2 days (interday) with different analysts (between analysts).
The results are presented in Table 5.
3.6.3. Accuracy
Accuracy of the bioassay method was evaluated at 80%, 100% and
120% of the nominal analytical concentration in the speciﬁed
range of 2.56–6.25 mg/mL. The mean accuracy was 101.23% with
RSD 0.72%, which conﬁrms the ability of the method to determine
with accuracy the Levoﬂoxacin concentration within the range of
80%120%. The results are shown in Table 6.
3.6.4. Robustness
The robustness of the bioassay was determined by analyzing the
same sample under a variety of conditions. To assess the
robustness some parameters were modiﬁed from the normal tested
conditions: solvent used for the standard and sample dilution
(distilled water), inoculum concentration (1.5%) and incubation
temperature (30 1C). Changing the experimental conditions to the
speciﬁed parameters, no signiﬁcant differences on the potencies
were observed as shown in Table 7.
3.7. Identiﬁcation by FTIR spectroscopy
Spectrum obtained from a commercial sample Levoﬂox tablet
was compared with a reference standard of Levoﬂoxacin. The full
IR spectrum of the commercial sample Levoﬂox showed char-
acteristic peaks similar to those of the reference standard ofLevoﬂoxacin (Fig. 3A and B). These peaks are known to be used
in the identiﬁcation of Levoﬂoxacin.
3.8. Correlation of microbial bioassay results and HPLC
The correlation between microbial bioassay and HPLC methods
was evaluated using the commercial sample Levoﬂox.
The obtained chromatograms of the commercial sample (Levoﬂox)
and reference standard of Levoﬂoxacin showed symmetrical peaks
having peak area 9,458,400 and 9,817,344, respectively (Fig. 4A
and B). The data in Table 8 indicate percentage potency of
Levoﬂoxacin determined by the bioassay compared to the percen-
tage potency assayed by the HPLC method. The potency of
Levoﬂoxacin in Levoﬂox tablet was determined as 99.37%
through the HPLC method whereas potency observed through
the bioassay was 100.90%. The content of Levoﬂoxacin in
Levoﬂox tablet obtained through both the methods was signiﬁ-
cantly identical. However, the observed minute deviation may be
due to the considerable differences between the two distinct
methods, such as experimental condition and detection technique.4. Discussion
The choice of a suitable analytical method is fundamental for
quality control of the medicines and is based on several factors like
drug source, its complexity, sample quantity, availability of
Fig. 3 FTIR absorbtion spectra of Levoﬂoxacin. (A) Reference standard; (B) commercial sample Levoﬂox.
N.A. Dafale et al.24equipments and reagents. Literature survey showed the use of
HPLC or other chemical methods for potency estimation of
Levoﬂoxacin in pharmaceutical preparation. Yet no microbiologi-
cal bioassay is available for potency determination of Levoﬂoxacin
in any pharmacopoeia. Although HPLC is a fast method for
potency determination of an antibiotic, it cannot determine
bioactivity. However, the microbiological assay estimates both
potency and bioactivity of antibiotics. Additionally, bioassay can
be used to estimate the effective dose against antibiotic-resistant
microbes. So, through this article we made an attempt to develop
and validate a microbiological bioassay as a suitable and simple
method for the quantiﬁcation of Levoﬂoxacin in pharmaceutical
preparations.
Compared to chemical methods, microbiological assay mea-
sures the true response of antibiotics on a biological system and it
is used to obtain more realistic and precise measurements of
potency. The bioassay methods used for potency determination are
the key determinants in generating reproducible and reliable data,
which are used in quality control of the medicine [29]. Micro-
biological bioassay is advantageous because the parameters that
are measured with these techniques and the properties for the drug
used are the same. Thus, impurities and the related substances donot interfere, maintaining the precision of the analytical method
[30]. Therefore, microbiological bioassay remains, in general, the
standard for resolving doubts with respect to possible loss of
activity [4].
The use of bacterial strains was found in some articles to test the
activity of Levoﬂoxacin. However, technical details about the
methodology and the validation of bioassay method were not
described. Rodriguez et al. [27] evaluated the in vitro activity of
Levoﬂoxacin against different strains of M. tuberculosis. Similarly,
the concentration of Levoﬂoxacin in ophthalmic solution was
measured using B. subtilis ATCC-6633 [26]. In the proposed study
16 strains of bacteria were tested for their response and suscept-
ibility against Levoﬂoxacin. Although most of the tested strains
showed susceptibility against Levoﬂoxacin, B. pumilus ATCC-
14884 was selected as the most signiﬁcant microbial strain because
of its high response and capacity to form sharply deﬁned zone of
inhibition.
To quantify an antibiotic through microbial bioassay, the
inoculum concentration should be validated, which showed sharp
and clear antibiotic zone of inhibition [31]. An inﬂuence of
inoculum concentration on resulting zone size is widely recog-
nized and experiments were performed to determine how critical
Fig. 4 HPLC chromatograms of Levoﬂoxacin. (A) Reference stan-
dard; (B) commercial sample Levoﬂox.
Table 8 Percentage potency of Levoﬂoxacin in a commer-
cial sample (Levoﬂox tablet) obtained by the bioassay and
HPLC methods.
Sample Potency (%)
Bioassay HPLC
1 101.52 100.08
2 100.60 98.11
3 102.84 100.27
4 99.88 98.45
5 100.42 99.79
6 100.14 99.52
Mean potency (%) 100.90 99.37
Validated microbial bioassay for quantiﬁcation of Levoﬂoxacin 25the concentration of inoculum might be, when other factors are
constant [31,32]. Approximately 2 105 CFU/mL of inoculum
suspension of B. subtilis ATCC-6633 was used in a cylinder agar
plate method to measure the concentration of Levoﬂoxacin in
ophthalmic solution [26]. Wide variation in the concentration of
microorganism produces different zone diameters. High inoculum
concentration of the test microorganism showed small zone
diameter and hazy growth pattern, whereas low concentration of
inoculum showed light and larger zone diameter. Thus, optimiza-
tion of inoculum concentration is necessary for a bioassay. In the
proposed study six different inoculums concentrations, i.e., 0.5%,
1.0%, 1.5%, 2.0%, 2.5% and 3.0%, of microbial strains were
tested and the optimum inoculum concentration of B. pumilus
ATCC-14884 was selected as 2.0% for the microbial bioassay.
One of the critical factors that inﬂuence the rate of microbial
growth is buffer pH. In the current study, the activity of
Levoﬂoxacin was studied in a range of phosphate buffers pH
6.0–8.0 and phosphate buffer pH 7.0 was found suitable for the
signiﬁcant growth of B. pumilus ATCC-14884 and the production
of measurable sharp zone of inhibition. Another important subjectis the selection of antibiotic concentration range. Different con-
centrations of Levoﬂoxacin, i.e., 0.06, 0.125, 0.25, 0.5, 1, 2, 4, 8
and 16 mg/L, were used against several strains of M. tuberculosis
[27]. In the proposed bioassay, the zone of inhibition was
measured for the range of selected concentrations of the reference
standard. The concentrations of reference standard of Levoﬂoxacin
were selected as 2.56, 3.20, 4.0, 5.0 and 6.25 mg/mL against the
tested microorganisms. Reasons for the selected range of concen-
tration were the susceptibility of microorganism to low concentra-
tion, size of the zones of inhibition that was limited by the size of
Petri dish for high concentration and linear relationship between
the logarithm of concentration and mean zone diameters. The
calibration value of Levoﬂoxacin was constructed by plotting the
logarithm of antibiotic concentration (mg/mL) versus mean dia-
meter of inhibition zone (in mm) and good linearity was found in
the range of the selected concentrations of the reference standard.
A comparative study of microbiological bioassay was also
carried out with the HPLC method and the potency of Levoﬂox-
acin was estimated as 100.90% and 99.37%, respectively. The
equivalence in results shows a strong correlation between these
two methods. However, estimating the bioactivity microbiological
assay is an effective method of determining the subtle change in
the antibiotic.5. Conclusions
A standard validated analytical method is mandatory for the
maintenance of quality of pharmaceutical preparations. In the
literature, mostly HPLC assay was found for the measurement of
Levoﬂoxacin concentration in different preparations. However, a
validated microbial bioassay method for the potency assessment of
Levoﬂoxacin in pharmaceutical preparation has not yet been
reported in any pharmacopoeias. Bioactivity of an antibiotic can
be determined only by the microbial bioassay method, which is the
main advantage over the HPLC method. Although both bioassay
and HPLC methods are complementary to each other, due to the
estimation of both potency and bioactivity by bioassay it seems to
be the most suitable method.
Experimental results show the signiﬁcance of the proposed
bioassay method in estimating the potency and bioactivity of
antibiotic by comparing their quantitative effect with a reference
standard of deﬁned potency. The optimization of the bioassay was
performed using various conditions and B. pumilus ATCC-14884
was selected as the most susceptible organism against Levoﬂox-
acin. Several factors were also examined such as buffer pH,
inoculums concentration and standard solution concentration. The
commercial sample Levoﬂox tablet was analyzed by the bioassay
and the percentage potency was determined as 100.90%. The
speciﬁcity of bioassay was correlated with the HPLC method and
the potency was estimated as 100.90% and 99.37%, respectively,
which are signiﬁcantly identical. The obtained results show that
both methods are reliable for potency estimation of Levoﬂoxacin.
Moreover, bioassay is less expensive and is appropriate while
investigating drug dynamics and bioactivity.Acknowledgments
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